Roche Holding AG

Roche Holding AG

Roche Holding AG

Overview
Date Founded

1966

Headquarters

Grenzacherstrasse 124,Basel, Basel-Stadt (Basle Town) 4070

Type of Company

Public

Employees (Worldwide)

94.4K

Industries

Pharmaceuticals
Wholesale: Consumer Non-Durables/Sundries
IT Consulting & Services
Holding Companies
Medical Support Services
Biotechnology

Company Description

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Contact Data
Trying to get in touch with decision makers at Roche Holding AG? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Chief Financial & Information Technology Officer

General Counsel

General Counsel

Chairman & Chief Executive Officer of Chugai

Secretary-Executive Committee & Head-Chief Executive Officer Office

Member of the Enlarged Corporate Executive Committee, Global Head Pharma Partnering

Chief Medical Officer & Head of Global Product Development

Global Head, Neurodegeneration

Head-Cancer Immunotherapy Discovery

Board of Directors

Honorary Professor at University of St. Gallen

Treasurer & Director at Fondation Auxiliaire du Conservatoire botanique de la Ville de

Chief Executive Officer at Roche Holding AG

Manager at ESCP Europe Campus Paris

Group Chief Executive Officer at Swiss Life Holding AG

Senior Adviser at GHO Capital Partners LLP

Former Senior Physician, Orthopedic Hospital at University of Basel

President at The Rockefeller University

Future Member, Board of Directors at Roche Holding AG (Effective 03/2020)

General Counsel at Roche Holding AG

Paths to Roche Holding AG
Potential Connections via
Relationship Science
You
Roche Holding AG
Owners & Shareholders
Details Hidden

Dodge & Cox employs in-house fundamental bottom-up research, a rigorous valuation discipline, and maintains a long-term investment horizon. Their investment decisions are made by a team of seasoned investment professionals. The firm's approach stresses an evaluation of risk relative to opportunity and they seek investments that they believe are undervalued by the market.

Details Hidden

APG follows a highly diversified approach to asset allocation and invest across a range of asset classes and regions. The firm applies a multi-alpha strategy to spread risk and seek high returns. Their internally-managed fund range includes Commodities, Developed Markets Equity, Developed Markets Equity Minimum Volatility, Emerging Markets Equity, Emerging Markets Debt, Europlus Treasuries, Hedge fund, Fixed Income Credits, Index Linked Bonds, Infrastructure, Long Duration Treasuries, Private Equity, Strategic Real Estate and Tactical Real Estate funds. Their research and documentation team initiates, formulates and evaluates active investment strategies and develops quantitative investment models used to determine the effectiveness of investment decisions. The team also acts as an advisory body for the Board and fund managers with respect to investment decisions.

Details Hidden

Diametric Capital LP is a private company headquartered in Boston, MA, with subsidiaries in the United States. The firm provides investment advice. It was founded in 2016 by Nainoor Chandres Thakore, he has been the CEO since then.

Recent Transactions
Details Hidden

Roche Holding AG purchases Promedior, Inc. from HealthCare Ventures LLC, Polaris Partners, Easton Capital Investment Group, Forbion Capital Partners Management Holding BV, Morgenthaler Management Corp., BioMed Ventures

Details Hidden

Fuji Chemical Industries Ltd. purchases Chugai Pharmaceutical Co. Ltd. /Ulcerlmin Bus from Roche Holding AG

Details Hidden

Roche Holding AG purchases Spark Therapeutics, Inc.

Transaction Advisors
Legal Advisor

Advised onRoche Holding AG purchases Genentech, Inc.

Investment Advisor

Advised onKoninklijke DSM NV purchases Roche Holding AG /Roche Vitamins Unit from Roche Holding AG

Investment Advisor

Advised onRoche Holding AG purchases InterMune, Inc.

Legal Advisor

Advised onRoche Holding AG purchases InterMune, Inc.

Legal Advisor

Advised onRoche Holding AG purchases InterMune, Inc.

Legal Advisor

Advised onRoche Holding AG purchases Genentech, Inc.

Advisors & Consultants
Advisor

Executive Vice President, Global Development & Chief Medical Officer at Genentech, Inc.

Advisor

Executive Vice President & Chief Investment Officer at Connecticut Innovations, Inc.

Advisor

Partner at Centerview Partners LLC

Clients

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its two main products are Ampyra and Zanaflex Capsules. The Ampyra is an oral drug, which treats to improve walking in patients with multiple sclerosis and Zanaflex Capsules, which is a short acting drug for the management of spasticity, a symptom of many central nervous system disorders, including multiple sclerosis and spinal cord injury. The company was founded by Ronald Cohen in 1995 and is headquartered in Ardsley, NY.

bioMérieux SA engages in the provision of diagnostic solutions, which determine the source of disease and contamination. The company provides clinical solutions such as antimicrobial resistance, C. difficile infection, human immunodeficiency virus, and emergency department patient management. It also specializes in the field of in vitro diagnostics. The company was founded in 1963 and is headquartered in Marcy l'Etoile, France.

Key Stats and Financials As of 2018
Market Capitalization
$259B
Total Enterprise Value
$218B
Earnings Per Share
$12.3
Revenue
$56.8B
Enterprise Value Sales
3.83x
Enterprise Value EBITDAOperating
10.71x
TEVNet Income
20.72x
Debt TEV
0.09x
EBITDAMargin
35.73%
Total Equity
$30.4B
EBITDA
$20.3B
Total Debt
$18.8B
Net Profit
$10.5B
Investments
Details Hidden

Vaccibody AS reates vaccines and immunotherapy. Its Vaccibody Vaccine Platform Technology is use for the variety of disease models including infectious diseases and cancer. The firm offers preclinical data for Vaccines against Human Papilloma Virus induced Cancer, Melanoma, Prostate Cancer, B Cell Lymphoma, and Multiple Myeloma showing the platform's ability to induce T cell responses and to eliminate cancer cells. Its therapeutic vaccines offer low-toxicity treatment options for early stage disease and enhance the efficacy of existing regimens in late-stage disease while adding minimal toxicity. The company was founded by Inger Sandlie on November 22, 2006 and is headquartered in Oslo, Norway.

Details Hidden

Eloxx Pharmaceuticals Ltd. provides biopharmaceutical research and development services. The firm specializes in the discovery, development, and commercialization of drug compounds for the treatment of genetic diseases. It focuses on the treatment of diseases caused by nonsense mutations, including Cystic fibrosis, Duchene Muscular Dystrophy, Usher syndrome, Ataxia-telangiectasia, Beta thalassemia, and Tay-Sachs Hurler syndrome. Its focus areas encompass clinical drug development and target drugs discovery programs. The company was founded by Silvia Noiman and Shmuel Tuvia in 2013 and is headquartered in Herzliya, Israel.

Details Hidden

cCAM Biotherapeutics Ltd. engages in the development of immunotherapies for different cancer indications. Its cCAM's lead agent, CM-24, is an immunomodulatory antibody that harnesses the patient's immune system to attack tumors. The company was founded in 2010 and is headquartered in Misgav, Israel.

Investors
Details Hidden

Life Peer at United Kingdom House of Lords

Details Hidden

Co-Founder at Cavendish Corporate Finance LLP

Details Hidden

Life Peer at United Kingdom House of Lords

Suppliers
Alexandria Real Estate Equities, Inc. Trusts & Funds | Pasadena, CA

Alexandria Real Estate Equities, Inc. is an urban office real estate investment trust, which engages in the ownership, operation, development, and redevelopment of life science and technology properties. It also provides a space for lease to the life science and technology industries which are primarily located in AAA urban innovation cluster locations. The company was founded by Alan D. Gold, Gary A. Kreitzer, Joel S. Marcus, and Jerry M. Sudarsky in October 1994 and is headquartered in Pasadena, CA.

Xenon Pharmaceuticals, Inc. Pharmaceuticals | Burnaby, BC

Xenon Pharmaceuticals, Inc. engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P. Kastelein, and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Exelixis, Inc. Biotechnology | SOUTH SAN FRANCISCO, CA

Exelixis is a biopharmaceutical company committed to developing and commercializing small molecule therapies for the treatment of cancer. In advancing our first product, COMETRIQ, from discovery to market, we have established an effective and integrated infrastructure that encompasses the entire biopharmaceutical development continuum. We are committed to excellence in all aspects of our work and are dedicated to improving the care and outcome of cancer patients.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Roche Holding AG. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Roche Holding AG's profile does not indicate a business or promotional relationship of any kind between RelSci and Roche Holding AG.